Brought to you by 
Flamel Technologies licenses BMS diabetes drug; terminated
23 May 2013
Executive Summary
Drug delivery company Flamel Technologies SA licensed Bristol-Myers Squibb exclusive worldwide development and marketing rights to Basulin, its controlled-release human insulin candidate, which is ready to enter Phase II clinical trials for Types I and II diabetes. Basulin is a once-daily injection that uses Flamel's Medusa protein delivery technology.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Flamel Technologies licenses BMS diabetes drug; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice